Saturday, February 11, 2006


Hepatitis C Virus Lives In Your Liver(NC)-Your liver (Hep C Treatment)

Hepatitis C Virus Lives In Your Liver

(NC)-Your liver works 24 hours a day, performing over 500 vital functions for your body. Most of the blood that returns to your heart passes through the liver. Your body can't function without it.

The hepatitis C virus lives in your liver. It inflames liver cells, which, over time, affects the way your liver functions. The effect of the hepatitis C virus varies from person to person. There is no way to predict how your body will react to it. There are, however, some things that are known:

You can live with hepatitis C for many years without experiencing any major symptoms, or you might simply feel tired. Symptoms can come and go over time. Their presence or absence does not tell you the degree to which liver damage may or may not be occurring. p>

Chronic, long-term inflammation of the liver can cause liver cell damage and result in fibrosis (liver scarring), or even cirrhosis. This damage can occur in as little as five years, or as long as 30 years.

About 20% of chronic hepatitis patients develop cirrhosis within 10 to 20 years.

Use of recreational drugs or alcohol can speed up inflammation and the development of fibrosis or cirrhosis.

There is an increased risk of liver cancer in people with cirrhosis.

The good news is that current drug treatments can be very effective for people with hepatitis C. Combined with proper nutrition, plenty of rest, and avoidance of recreational drugs and alcohol, these treatments help many who have the virus lead relatively healthy lives.

If you think you may be at risk of getting hepatitis C, see your doctor. The virus can be detected by a simple blood test. For more information on how to keep your liver happy and healthy, visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

p>

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services. p>


Friday, February 10, 2006


Re:Wheres My Hair (Hep C Treatment)


Re:Wheres My Hair
Blink: Hepatitis C Added by glog as long as we are being ladies tonight, >> HELL... I guess we can just start calling ourselves "The Classy Lassies of the Hep-C Tribe" LOL...LOL...LOL!!!!!!!!!!!!!!!!!!!!!!!!!!!! Oh well... What the worth use in living... if you can't [b]...[/b]... [url=http://hepatitisc.tribe.net/thread/f8e18c6e-6675-4281-9a5d-eae53bc6f4b3#ecd9ea41-4463-4352-924a-acb23aef876d]Read more...[/url] Discover Cool New Cars

Vaccination Tames Hepatitis A Infection
Title: Vaccination Tames Hepatitis A InfectionCategory: Health NewsCreated: 7/13/2005 1:58:00 AMLast Editorial Review: 7/13/2005 1:58:14 AM

Hepatitis C
Title: Hepatitis CCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

Pegasys Shown More Effective In Study
Schering and Roche are taking part in dueling press releases. Each claiming their solution is better. Either way, they seem to be splitting hairs regarding effectiveness. There is no clear winner when they keep firing PR salvos back and forth....

Vertex Progresses with VX-950
Vertex is the racehorse to watch right now. They are progressing quicky on their preliminary good results. While it's not yet time to line up for their treatment, we believe theirs will be first to market of the new approaches...

Immunization: National Immunization Awareness Month (Hep C Treatment)


Immunization: National Immunization Awareness Month
Title: Immunization: National Immunization Awareness MonthCategory: Health FactsCreated: 8/1/2005Last Editorial Review: 8/1/2005

Doctor: Checklist to Take To Your Doctor's Appointment
Title: Doctor: Checklist to Take To Your Doctor's AppointmentCategory: Health FactsCreated: 7/13/2005Last Editorial Review: 7/14/2005

Hepatitis B
Title: Hepatitis BCategory: Diseases and ConditionsCreated: 1/26/2001 11:58:00 AMLast Editorial Review: 9/21/2005

Thursday, February 09, 2006


ILAR Journal Online, Volume 42(2) 2001: Animal Models of Hepatitis (Hep C Treatment)


ILAR Journal Online, Volume 42(2) 2001: Animal Models of Hepatitis
Viral heaptitis, type B in experimental animals. Am J Med Sci 270:189-195. Bassett SE, Thomas D, Brasky, KM, Lanford RE. 1999. Viral persistence antibody to E1 and E2, and hypervariable region 1

Hepatitis C Treatment Options
in the treatment of mutant type chronic viral heaptitis B 23-Oct-2002 Hepatitis C and Hepatitis Berquist KR, London WT. 1975. Viral heaptitis, type B in experimental animals Gastroenterology

Nurses and Hepatitis C
Coinfection HIV & Viral Heaptitis: a guide December 2003 Third Edition Produced in Association with the Australian Liver Association, Gastroenterological Society of Australia, Australian Hepatitis

hbv_research
does not increase the efficacy of interferon in the treatment of mutant type chronic viral heaptitis B 23-Oct-2002 Hepatitis C and Hepatitis B Virus Infection in Different Hemodialysis Units in Belo

World J Gastroenterol
does not increase the efficacy of interferon in the treatment of mutant type chronic viral heaptitis B. Yang SS, Hsu CT, Hu JT, Lai YC, Wu CH. World J Gastroenterol 8(5):868-871 Mutational

Lamivudine does not increase the efficacy of interferon in the
does not increase the efficacy of interferon in the treatment of mutant type chronic viral heaptitis B World J Gastroenterol 2002 Oct;8(5):868-71Related Articles, Links Lamivudine does not increase

AVI BioPharma in Chiron licensing deal (Hep C Treatment)


AVI BioPharma in Chiron licensing deal
BusinessWeek - JAN. 27 11:51 A.M. ET AVI BioPharma Inc., a biopharmaceutical company, said Friday Chiron Corp. granted AVI a nonexclusive license to Chiron's patents for hepatitis C virus, or HCV, antisense therapeutics drugs. Chronic HCV infection causes liver

January truck market starting strong
Sunday Times South Africa - The SA heavy commercial vehicle (HCV) market started the new sales year on a strong note, substantially exceeding the 12% annual growth rate needed to ensure 2006 becomes a new outright record sales year, Nissan Diesel South Africa notes. The segment

First-Time Generic Approvals: Copegus, Tegretol, Roxicodone
Medscape News - Jan. 24, 2006 The US Food and Drug Administration (FDA) approved in December 2005 first-time generic 200-mg formulations of ribavirin and carbamazepine tablets, and 15- and 30-mg formulations of oxycodone HCl tablets. First-time doses (ie, no

Wednesday, February 08, 2006


Hepatitis C Patients Taxing Medical System (Hep C Treatment)


Hepatitis C Patients Taxing Medical System
MedicineNet.com - Jan 27 4:21 AM
Title: Hepatitis C Patients Taxing Medical System Category: Health News Created: 12/31/2005 1:59:00 AM Last Editorial Review: 12/31/2005 1:58:37 AMSave to My Web

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study In Patients Coinfected With Hepatitis C And HIV
Medical News Today - Jan 15 4:17 PM
Schering-Ploughannounced today that it is initiating a large multinational clinical trial toevaluate the use of low-dose PEG-INTRON(R) (peginterferon alfa-2b) maintenancemonotherapy in preventing or delaying hepatitis C disease progression and thuspotentially reducing the occurrence of clinical events such as livertransplantation, liver cancer and death in cirrhotic patients with hepatitis Cwho Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 12:56 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

Schering-Plough Drug Gets Fast Track
AP via Yahoo! Finance - Jan 30 6:44 AM
Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment.Save to My Web

Peregrine Accelerates Tarvacin HCV Study
AP via Yahoo! Finance - Jan 18 5:28 AM
Biopharmaceutical company Peregrine Pharmaceuticals Inc. said Wednesday that it is accelerating its program to test its cancer drug Tarvacin for the treatment of hepatitis C.Save to My Web

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in ... (Hep C Treatment)


Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in ...
RxPG NEWS, CA - Jan 18, 2006By Peregrine Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio ...

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral ...
Biotech Intelligence (press release), France - Jan 18, 2006TUSTIN, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a biopharmaceutical company with ...

Peregrine Announces Acceleration of Its Tarvacin Anti-Viral ...
PharmaLive.com (press release), PA - Jan 18, 2006TUSTIN, Calif., Jan. 18, 2006 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio ...

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral ...
Yahoo! News (press release) - Jan 18, 2006TUSTIN, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company ...

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral ...
PR Newswire (press release), NY - Jan 18, 2006- Patient Enrollment and Dosing in Initial Phase I Trial Now Scheduled for Completion in February - - Preliminary Phase I Safety Data to Be Presented at 'Viral ...

Tuesday, February 07, 2006


A Summary of Chronic Hepatitis C InfectionHepatitis C (Hep C Treatment)

A Summary of Chronic Hepatitis C Infection

Hepatitis C is a stealthy virus that mutates while hiding in liver cells and other organ cells like the spleen and gall bladder. The fact that the viral cells "hide" makes it very difficult for the body's immune system to eradicate it. Hepatitis C is a slowly progressing disease sometimes taking many years until symptoms are noticeable. It is at this point that the virus has reached advanced chronic stage and becomes difficult to eradicate. Hepatitis C results in 8,000 to 10,000 deaths annually. Hepatitis C is also the leading cause of liver transplants in the U.S.

Hepatitis C infection is caused by blood contact with someone who has the virus infection himself. The transmission of the virus can occur by illicit drug use with needles, sharing toothbrushes or razors with an infected person, by sexual means, by unsanitary tattooing or by exposure to blood at your workplace (like a hospital or blood bank). Some HCV infection may have been caused by receiving blood from a transfusion prior to 1992.

Hepatitis C is diagnosed via a blood test. Usually, the first thing that is noticed is that the liver enzyme levels for ALT and AST are elevated well above normal levels. Further investigation via HCV-RNA testing identifies whether the Hepatitis C virus is in your blood or not. Other tests for HCV include qualitative viral load tests, which measure the RNA particles in your blood. If you are being treated for HCV, your doctor is probably using either a HCV-RNA or viral load test to determine the effectiveness of the treatment.

The symptoms of Hepatitis C infection often do not occur in a person until 20 years after he/she had been infected. Since the HCV infects the liver and the liver is the organ in the body that makes all the energy for our daily activities possible, liver function deterioration often results in fatigue. Fatigue is the primary complaint or symptom of HCV infection. Other more severe symptoms are jaundice (yellowing of the skin/eyes), bile retention (which can cause jaundice), portal vein hypertension, skin rashes and itching, and autoimmune problems resulting from your body's immune system attacking normal cells.

Long term HCV infection may result in fibrosis or even cirrhosis of the liver. Fibrosis results from unchecked liver inflammation. As the HCV infection progresses, the damage to the liver results in scarring or hardening of the liver cells (fibrosis). Long term fibrosis may lead to cirrhosis which is when the scarring from fibrosis overtakes the normal liver cell structure causing deformity and loss of function in the liver. About 15%-20% of HCV patients end up with cirrhosis. A liver biopsy is currently the most accurate means of determining the amount of inflammation and fibrosis the liver has sustained.

Hepatitis C progression in the body can take several years or even decades to come to chronic stage or to a stage where severe liver damage is evident. This period of time allows a person to determine how to properly treat the disease and to decide on a course of disease management. Currently, the main treatment for HCV infection to eradicate the virus is combo alpha-interferon and Ribavirin. Sometimes a doctor may prescribe interferon alone. Interferon comes in standard form or in pegylated form. Standard form interferon is administered 3 times per week, while the pegylated form is administered only once per week. Your body makes its own interferon, which is a protein that fights viral infection and viral replication.

Hepatitis C may often be managed by taking herbal and vitamin supplements that help your body fight infection and limit inflammation. These supplements help your liver with the inflammation and give it the nutrients it needs to regenerate healthy new cells. Your doctor can recommend alternative or adjunct solutions you may want to try.

Proper treatment of the disease, a healthy and active lifestyle, a good diet, abstinence from alcohol and stress management are important factors in controlling Hepatitis C progression.

About the Author

Greg Lietz is a freelance writer and internet businessman. His main website is http://www.theonlinebizplace.com where he provides content about internet based business opportunities and different niche interests. This article may be freely printed when the bio information is included.

Hepatitis C Patients Taxing Medical System (Hep C Treatment)


Hepatitis C Patients Taxing Medical System
Title: Hepatitis C Patients Taxing Medical SystemCategory: Health NewsCreated: 12/31/2005 1:59:00 AMLast Editorial Review: 12/31/2005 1:58:37 AM

Immunization: National Immunization Awareness Month
Title: Immunization: National Immunization Awareness MonthCategory: Health FactsCreated: 8/1/2005Last Editorial Review: 8/1/2005

Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a shorter course of treatment might be just as effective as longer courses. Researchers continue to refine treatment protocols for HCV...

Monday, February 06, 2006


Bid to remove biopsy barrier to hep C treatment (Hep C Treatment)


Bid to remove biopsy barrier to hep C treatment
AustralianDoctor.com (subscription), Australia - Jan 10, 2006By Bianca Nogrady. PATIENTS with hepatitis C will no longer need a liver biopsy to qualify for subsidised treatment with antiviral ...


Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration (Hep C Treatment)


Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

The Pathway of HCV IRES-Mediated Translation Initiation (PDF) (Hep C Treatment)


The Pathway of HCV IRES-Mediated Translation Initiation (PDF)
... The Pathway of HCV IRES-Mediated. Translation Initiation ... a 12% SDS-PAGE gel of time points from HeLa S10 in vitro translation of 100 nM wild-type HCV IRES lucifer ...

Hepatitis C - Wikipedia, the free encyclopedia - Translate this page
... The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the ...

HCV Advocate
information on the symptoms, prevention, and treatment of the virus.

Sexual Transmission of HCV Is Rare in Monogamous Heterosexual...
In a 10-year prospective study of these couples who abstained from anal intercourse or vaginal intercourse during menstruation, risk of sexual transmission of hepatitis C virus was extremely low or even null. ... included patients from an internal medicine practice with positive anti-HCV antibody and HCV RNA tests ... partner who had tested negative for HCV. Partners of HCV-infected patients ...

Role of the 5 -Proximal Stem-Loop Structure of the 5 Untranslated (PDF)
... (HCV) RNA genome are highly conserved and contain cis-acting RNA elements for HCV RNA replication. The. HCV 5 UTR consists ...

Sunday, February 05, 2006


Hepatitis C (Hep C Treatment)


Hepatitis C
Jackson Gastroenterology's Web Site includes office information and paient education material on digestive and liver disorders, and nutrition. Endoscopic procedures that help in diagnosis and treatment are also described. ... What is Hepatitis C? Hepatitis C is caused by a virus (medically abbreviated as HCV). This type of viral hepatitis ... However, the hepatitis C virus is a "quick-change" artist ...

Hepatitis Research Foundation-Home
Home page for the hepatitis research foundation (formerly, the hepatitis C research foundation)

Chronic Hepatitis C: Current Disease Management
from the National Institutes of Health. Resources on the treatment of hepatitis C as well as risk factors, symptoms, and diagnosis.

Hepatitis C
An Important. Message from. Dr. Koop. Contents. Search. Glossary. About the Site

WHO | Hepatitis C (Hep C Treatment)


WHO | Hepatitis C
Hepatitis C is a viral infection of the liver which had been referred to as ... The discovery and characterization of the hepatitis C virus (HCV) led to the ...

HEPATITIS C INFO CENTER - With Daily Hepatitis C Updates
Find all the Hepatitis C information you are looking for, over 2500 pages, INCLUDING THE LATEST NEWS about infection, symptoms and treatment...

Hepatitis C: Current Treatment
The main goal of treatment of chronic hepatitis C is to eliminate detectable viral ... Lack of detectable hepatitis C virus RNA from blood six months after ...

Hepatitis Central, Current Information On Hepatitis C & treatments ...
Hepatitis C Information Center at Hepatitis-Central.com Featuring the latest news about Hepatitis C infection, Hepatitis C diagnosis, Hepatitis C symptoms, ...